PepEvolutionCagriSema
Novo Nordisk's fixed-dose amylin + GLP-1 combo in phase-3 REDEFINE — up to 22% weight loss in early data.
Verdict — C · Emerging / Mixed
Additive amylin+GLP-1 mechanism with strong early data, but no approval and the REDEFINE-1 readout was mixed vs expectations in 2024. Gray-market material is unverifiable. A C pending a decisive phase-3 read.
Overview
CagriSema is a fixed-dose combination of cagrilintide (long-acting amylin analogue) and semaglutide 2.4 mg in phase-3 REDEFINE trials. Early phase-2 results showed approximately 15-22% weight loss, exceeding semaglutide alone. Neither component is approved as a combination, and no verified supply exists outside the clinical program.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.